You are here: Industry Insights > Hikma

News List

Hikma Acquires Teligent Sterile Injectable Assets for $45.75M contractpharma
January 17, 2022
Marks Hikma's expansion into Canada and includes a portfolio of 25 sterile injectable products.
Hikma boosts US injectables business with $425 million deal for Custopharm CPhIonline
October 13, 2021
The acquisition will add 13 approved products and additional pipeline products
Hikma Pharma get US FDA nod for higher dosage of nasal spray product to treat opioid overdose expresspharma
May 07, 2021
The US Food and Drug Administration (US FDA) announced the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose.
Hikma get US FDA nod for higher dosage of naloxone nasal spray to treat opioid overdose expresspharma
May 07, 2021
The US Food and Drug Administration (US FDA) announced the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose.
Hyloris Announces Major Commercial Partnership in the U.S. for Maxigesic® IV americanpharmaceuticalreview
April 30, 2021
Hyloris Pharmaceuticals SA, has announced that its partner for Maxigesic IV, AFT Pharmaceuticals, has signed an exclusive license and distribution agreement with Hikma Pharmaceuticals for the U.S. commercialization of Maxigesic IV, a novel, patented ...
Hikma, GSK stop talks over potential buyout deal of Egypt, Tunisia assets expresspharma
March 12, 2021
Hikma Pharmaceuticals and GlaxoSmithKline have ended talks over a potential buyout deal for the latter’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia, the companies said.
Hikma intends to acquire assets in Egypt, Tunisia expresspharma
January 27, 2021
Hikma Pharmaceuticals said it was planning to buy GSK’s stake in some assets including the drugmaker’s pharma, consumer commercialisation and manufacturing business in Egypt and its drugs business in Tunisia.
Sun Pharma and Hikma enter into exclusive licensing agreement for ILUMYA for Middle East & North Africa regions expresspharma
June 16, 2020
ILUMYA (tildrakizumab) is an US FDA approved innovative IL-23p19 monoclonal antibody used for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Hikma picks up Insys naloxone spray, equipment in $12M bankruptcy buy fiercepharma
August 22, 2019
The carcass of pain drug wheeler-dealer Insys Therapeutics is being pieced off in bankruptcy court, and Hikma Pharmaceuticals says it has picked up some of those pieces.
Hikma and Richter sign pact to market cariprazine in MENA biospectrumasia
July 29, 2019
Richter will be responsible for product supply and Hikma will proceed with the registration and commercialisation of the product

Previous page 1 2 3 Next page